← Back to Search

Anti-metabolites

Vandetanib for Lung Cancer (ZEAL Trial)

Phase 3
Waitlist Available
Research Sponsored by Genzyme, a Sanofi Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up time to death in months
Awards & highlights
Pivotal Trial

Summary

This trial is testing if adding vandetanib to the existing lung cancer drug Alimta (pemetrexed) is more effective for patients with advanced non-small cell lung cancer who have already been treated. Vandetanib helps by blocking signals that allow cancer cells to grow and get blood supply. Vandetanib is taken orally and has been studied for its effectiveness and safety in advanced lung cancer.

Eligible Conditions
  • Lung Cancer
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time to death in months
This trial's timeline: 3 weeks for screening, Varies for treatment, and time to death in months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Progression-Free Survival (PFS) in the Female Population
Progression-Free Survival (PFS) in the Overall Population
Secondary study objectives
Disease Control Rate (DCR)
Duration of Response (DoR)
Erythrocyte Indices
+5 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: 2Experimental Treatment2 Interventions
Vandetanib + Pemetrexed
Group II: 1Placebo Group1 Intervention
Placebo Vandetanib + Pemetrexed
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vandetanib
2007
Completed Phase 3
~5790
Pemetrexed
2014
Completed Phase 3
~5550

Find a Location

Who is running the clinical trial?

Genzyme, a Sanofi CompanyLead Sponsor
527 Previous Clinical Trials
185,038 Total Patients Enrolled
Clinical Sciences & OperationsStudy DirectorSanofi
872 Previous Clinical Trials
2,020,090 Total Patients Enrolled

Media Library

Pemetrexed (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT00418886 — Phase 3
Lung Cancer Research Study Groups: 1, 2
Lung Cancer Clinical Trial 2023: Pemetrexed Highlights & Side Effects. Trial Name: NCT00418886 — Phase 3
Pemetrexed (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00418886 — Phase 3
~37 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top